Free Trial

Joint (NASDAQ:JYNT) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Joint logo with Medical background

Key Points

  • Joint (NASDAQ:JYNT) reported a quarterly earnings per share (EPS) of ($0.06), beating the consensus estimate of ($0.07) by $0.01.
  • The company has authorized a stock buyback plan allowing the repurchase of up to $5.00 million in shares, indicating a belief that its stock is undervalued.
  • Geode Capital Management LLC increased its stake in Joint by 17.6%, now holding 2.26% of the company, reflecting strong institutional interest.
  • Looking to Export and Analyze Joint Data? Unlock 5 Weeks of MarketBeat All Access for Just $5. Claim Your Limited-Time Discount.

Joint (NASDAQ:JYNT - Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.01, Zacks reports. Joint had a positive return on equity of 0.67% and a negative net margin of 7.02%. The firm had revenue of $13.27 million during the quarter, compared to the consensus estimate of $13.32 million.

Joint Price Performance

JYNT traded up $0.04 during trading on Friday, hitting $10.74. The company's stock had a trading volume of 54,106 shares, compared to its average volume of 43,802. The firm's 50 day moving average price is $11.47 and its 200-day moving average price is $11.11. The stock has a market cap of $164.32 million, a PE ratio of -32.55 and a beta of 1.53. Joint has a twelve month low of $9.58 and a twelve month high of $13.47.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the company. Lake Street Capital cut their price objective on Joint from $20.00 to $16.00 and set a "buy" rating for the company in a research report on Friday, May 9th. B. Riley cut their price objective on Joint from $20.00 to $18.00 and set a "buy" rating for the company in a research report on Friday.

Get Our Latest Stock Report on Joint

Joint declared that its Board of Directors has authorized a stock buyback plan on Thursday, June 5th that allows the company to repurchase $5.00 million in shares. This repurchase authorization allows the company to repurchase up to 2.7% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company's board believes its stock is undervalued.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Joint stock. Geode Capital Management LLC grew its stake in shares of The Joint Corp. (NASDAQ:JYNT - Free Report) by 17.6% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 345,330 shares of the company's stock after buying an additional 51,704 shares during the period. Geode Capital Management LLC owned 2.26% of Joint worth $3,986,000 as of its most recent SEC filing. Institutional investors and hedge funds own 76.88% of the company's stock.

About Joint

(Get Free Report)

The Joint Corp. operates and franchises chiropractic clinics in the United States. The company operates in two segments, Corporate Clinics and Franchise Operations. The Joint Corp. was incorporated in 2010 and is headquartered in Scottsdale, Arizona.

Further Reading

Earnings History for Joint (NASDAQ:JYNT)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Joint Right Now?

Before you consider Joint, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Joint wasn't on the list.

While Joint currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Growth Stocks That Could Pop Before Summer Ends
3 Buy-the-Dip Stocks Poised to Rebound Soon
Quantum Boom: 3 Strong Picks with Lower Risk

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines